Multinationals Start 2021 Empty Handed In China National Reimbursement Race
But Broader IO Indications An Advantage?
China's latest round of reimbursement decisions show multinationals including AstraZeneca, BMS and Roche won’t be receiving national coverage for their latest immuno-oncology drugs any time soon.
